Stemline Therapeutics Reports Fourth Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Stemline Therapeutics (STML) PT Trimmed at Wedbush; Shares Remain Undervalued
March 17, 2015 12:23 PM EDTWedbush analyst David Nierengarten reiterated an Outperform rating on Stemline Therapeutics (NASDAQ: STML) but trimmed his price target to $35.00 (from $49.00) after the company reported a smaller-than-expected Q4 loss. The target cut comes as they push out their launch timeline. However, they still view the stock... More
Stemline Therapeutics (STML) Misses Q4 EPS by 2c
March 16, 2015 7:12 AM EDTStemline Therapeutics (NASDAQ: STML) reported Q4 EPS of ($0.53), $0.02 worse than the analyst estimate of ($0.51).
Stemline ended the fourth quarter of 2014 with $58.6 million in cash, cash equivalents and investments, as compared to $65.0 million as of September 30, 2014. In January 2015, the Company completed an equity offering... More
